Quick Takeaways: Why It Matters? The FDA’s Emergency Use Authorization for Simparica Trio to treat New World screwworm (NWS) larvae in dogs gives veterinarians a convenient, oral option that can be used alongside existing livestock tools (e.g., Dectomax...
Quick Takeaways: Why It Matters? Parnell’s 50 mL PropofolVet Multidose should help veterinary practices match vial size to procedure volume, cutting waste and improving inventory efficiency while keeping the same propofol use cases and 28-day, no-refrigeration convenience. Marketwise, the ...
Quick Takeaways: Why It Matters? Credelio Quattro appears to have a clear speed-of-kill advantage over Simparica Trio and NexGard Plus, with the studies showing faster and more sustained tick kill through the full monthly dosing interval. That matters because quicker tick death lowers the ...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
Quick Takeaways Why It Matters? Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category. If LOY-002 secures conditional and then full approval, it could...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
